X0202 SCHEDULE 13G/A 0000919574-26-003212 0002115022 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 06/30/2026 0001430306 Tonix Pharmaceuticals Holding Corp. 890260839 200 CONNELL DRIVE, SUITE 3100 BERKELEY HEIGHTS NJ 07922 Rule 13d-1(b) Sirenia Capital Management LP b DE 0.00 814801.00 0.00 814801.00 814801.00 N 4.9 IA PN Includes 615,025 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants. Alex Silverstein b X1 0.00 814801.00 0.00 814801.00 814801.00 N 4.9 HC IN Includes 615,025 shares of Common Stock issuable upon exercise of warrants. Tonix Pharmaceuticals Holding Corp. 200 Connell Drive, Suite 3100, Berkeley Heights, NJ 07922 This statement is filed by: (i) Sirenia Capital Management LP ("Sirenia") with respect to the common stock, par value $0.001 per share ("Common Stock"), of Tonix Pharmaceuticals Holding Corp. (the "Issuer") held by, and issuable upon exercise of warrants held by, investment funds it manages (the "Sirenia Funds"); and (ii) Alex Silverstein ("Mr. Silverstein"), the managing member of Sirenia Capital Management GP LLC, the general partner of Sirenia, with respect to the Common Stock held by, and issuable upon exercise of warrants held by, the Sirenia Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. The address of the principal business office of Sirenia and Mr. Silverstein is 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139. Sirenia is a Delaware limited partnership. Mr. Silverstein is a United States citizen. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 15,940,801 shares of Common Stock outstanding as of May 8, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 11, 2026, and assumes the exercise of the warrants held by the Sirenia Funds. 4.9% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. N Y N See Item 2(a). N See Item 2(a) and Item 3. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Sirenia Capital Management LP /s/ Kolby Loft 08/14/2026 Alex Silverstein /s/ Alex Silverstein 08/14/2026